
Prelude Therapeutics (PRLD) Stock Forecast & Price Target
Prelude Therapeutics (PRLD) Analyst Ratings
Bulls say
Prelude Therapeutics is a precision oncology company that utilizes its platform to develop highly selective and differentiated small molecule medicines to address high unmet need in cancer therapy. The company has a strong pipeline, including clinical-stage assets targeting well-validated mechanisms, as well as early-stage programs such as its KAT6A degrader (PRT13722) for HR+/HER2- breast cancer. The company has also secured collaborations to help advance its programs, including an exclusive option for its JAK2V617F inhibitor program with Incyte Corporation. Financially, Prelude has a strong cash position and has raised additional capital, providing a solid runway to advance its programs. With a deep pipeline, emerging clinical validation, and strong partnerships, Prelude Therapeutics is well-positioned for multi-asset value creation and potential upside for investors.
Bears say
Prelude Therapeutics is facing a negative outlook due to the evolving landscape in precision oncology, with broad-spectrum kinase inhibitors being replaced by high-precision molecular targeting. The lack of selectivity in traditional inhibitors leads to dose-limiting toxicities, making precision targeting more desirable. Additionally, the company's patents for specific therapies may provide additional exclusivity and potential for partnerships, but it remains to be seen if these efforts will be successful.
This aggregate rating is based on analysts' research of Prelude Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Prelude Therapeutics (PRLD) Analyst Forecast & Price Prediction
Start investing in Prelude Therapeutics (PRLD)
Order type
Buy in
Order amount
Est. shares
0 shares